This medicine is now known as tanzisertib.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2018 on request of the sponsor.
On 9 December 2011, orphan designation (EU/3/11/934) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol for the treatment of idiopathic pulmonary fibrosis.
Treatment of idiopathic pulmonary fibrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
EU/3/11/934: Public summary of opinion on orphan designation: 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol for the treatment of idiopathic pulmonary fibrosis (PDF/144.88 KB)
First published: 20/12/2011
Last updated: 22/02/2018
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: